Thursday, 18 Jan 2018

You are here

Spinal Manipulation Equal to NSAIDS for Acute Low Back Pain

JAMA has published a review of 15 RCTs (1711 patients) analyzing the role of spinal manipulation therapy in patients with acute low back pain. The authors found modest improvements in pain and function at up to 6 weeks, with temporary minor musculoskeletal harms.

Back pain is among the most common symptoms prompting patients to seek care. Lifetime prevalence estimates of low back pain exceed 50 percent. Treatments for acute back pain include analgesics, muscle relaxants, exercises, physical therapy, heat, spinal manipulative therapy (SMT) and others, with none established as superior to others. Paul G. Shekelle, M.D., Ph.D., of the West Los Angeles Veterans Affairs Medical Center, Los Angeles, and colleagues conducted a review and meta-analysis of previous studies to assess the effectiveness and harms associated with spinal manipulation compared with other nonmanipulative therapies for adults with acute (six weeks or less) low back pain.

Of 26 eligible randomized clinical trials (RCTs) identified, 15 RCTs (1,711 patients) provided moderate-quality evidence that SMT has a statistically significant association with improvements in pain. Twelve RCTs (1,381 patients) produced moderate-quality evidence that SMT has a statistically significant association with improvements in function. No RCT reported any serious adverse event. Minor transient adverse events such as increased pain, muscle stiffness, and headache were reported 50 percent to 67 percent of the time in large case series of patients treated with SMT. Heterogeneity (differences) in study results was large, and was not explained by type of clinician performing SMT, type of manipulation, study quality, or whether SMT was given alone or as part of a package of therapies.

The authors write that the size of the benefit of SMT for acute low back pain is about the same as the benefit from nonsteroidal anti-inflammatory drugs, according to the Cochrane review on this topic.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

No surprise. Many of these patients will improve regardless of treatment or lack thereof UNLESS there are psychosocial "drivers". Time and placebo remain effective therapies unless the patient's perception of the meaning of the pain results in pain behavior. Many people live paycheck to paycheck and need a "quick fix" to get back to their life responsibilities and obligations. Activity modification or decreased income are not options for such patients.

More Like This

Cannibis Weakly Effective in Neuropathic Pain

The medical use of cannabis is often extended to management of chronic pain and neuropathic pain.

A metanalysis of 27 chronic pain trials show that there is low-strength evidence that cannabis alleviates neuropathic pain but insufficient evidence in other pain populations.

However, there was little evidence that cannabis can alleviate pain associated with multiple sclerosis, cancer, or rheumatic conditions.  

AASM Guidelines for Sleep Apnea Testing

A task force from the American Academy of Sleep Medicine (AASM) performed a systematic review of the scientific literature on obstructive sleep apnea and screening tests.

Fibromyalgia Diagnosed by Two Simple Tests

Researchers from the Oregon Health Science Center have reported that fibromyalgia can be distinguished from chronic pain by primary care providers (PCPs) who employ two simple screening tests: BP cuff-evoked pain and a single patient question, and pain induced by pinching the Achilles tendon. 

Opioid Crisis Costs US $500 Billion

Reuters reports that the opioid crisis has cost the United States as much as $504 billion in 2015,  based on a White House economists report released this week. The White House Council of Economic Advisers (CEA) said the toll from the opioid crisis represented 2.8% of gross domestic product that year.

DEA Cracks Down on Illicit Fentanyl

Reuters reports that  U.S. Drug Enforcement Administration (DEA) has declaed it would classify illicit versions of fentanyl at the same level as heroin, allowing criminal prosecution of anyone who possesses, distributes or manufactures illicit versions of the drug.